Filing Summary
Business context and reporting period: MindWalk Holdings Corp. furnished a Form 6-K for October 2026, reporting a director appointment announced October 1, 2026.
Key Disclosure
- Kim Remizowski was appointed to the board, effective September 29, 2026. The board determined that he qualifies as an independent director under Nasdaq rules and applicable SEC regulations.
- Effective September 29, he joined the Audit Committee and the Compensation, Nomination and Governance Committee.
- Mr. Remizowski has more than 35 years of institutional banking and fiduciary oversight experience. His prior roles include Director, Private Equity at Vistra, board service at Merrill Lynch Bank and Trust Company (Cayman) Ltd., Managing Director at DMS Bank & Trust Ltd., and 17 years at Royal Bank of Canada.
Financial Results and Changes
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics, and no comparable-period financial results.
Outlook, Risks and Contingencies
No financial guidance, outlook, material risks, contingencies, or unusual financial items are disclosed. The director appointment information is incorporated by reference into specified Form S-8 and Form F-3 registration statements. The attached press release is generally furnished, not filed, for Exchange Act Section 18 purposes.
Investor Verification Items
- Verify the registrant identity: the filing names MindWalk Holdings Corp., but its signature block identifies “IMMUNOPRECISE ANTIBODIES LTD.”
- Review Exhibit 99.1 for the full press release and any additional appointment details.
- Confirm the committee assignments and effective dates in subsequent company disclosures.